{
    "2021-11-09": [
        [
            {
                "time": "",
                "original_text": "强者不再恒强，Q3医药也有“弟弟”",
                "features": {
                    "keywords": [
                        "医药",
                        "Q3",
                        "强者",
                        "弟弟"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "沃森生物：公司13价肺炎结合疫苗正在摩洛哥进行注册申报",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "13价肺炎结合疫苗",
                        "摩洛哥",
                        "注册申报"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2021-04",
                "original_text": "沃森生物：子公司玉溪沃森生物技术有限公司于2021年4月与摩洛哥MarocVax Sarl公司就玉溪沃森生产的13价肺炎球菌多糖结合疫苗在摩洛哥的成品进口、分销、销售及其原液供应合作业务签订了独家经销协议",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "玉溪沃森",
                        "摩洛哥",
                        "独家经销协议",
                        "13价肺炎球菌多糖结合疫苗"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "沃森生物：公司新冠mRNA疫苗三期临床研究等相关的工作在正常推进中",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "新冠mRNA疫苗",
                        "三期临床研究"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "沃森生物：疫苗产品属于特殊商品，公司不能直接将疫苗产品卖给最终消费者",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "疫苗产品",
                        "特殊商品"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "沃森生物：公司与清华大学、天津医科大学合作研发的两个疫苗目前正开展二期临床试验",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "清华大学",
                        "天津医科大学",
                        "疫苗",
                        "二期临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "沃森生物：子公司上海泽润九价HPV疫苗正在开展Ⅲ期临床研究的各项前期准备工作",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "上海泽润",
                        "九价HPV疫苗",
                        "Ⅲ期临床研究"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "沃森生物：公司与清华大学、天津医科大学合作研发的重组新型冠状病毒疫苗（黑猩猩腺病毒载体）、子公司上海泽润研发的重组新型冠状病毒疫苗（CHO细胞）目前正在开展二期临床试验",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "清华大学",
                        "天津医科大学",
                        "重组新型冠状病毒疫苗",
                        "二期临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "沃森生物、天宇股份涨超10%，生物医药ETF（512290）涨超3.5%",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "天宇股份",
                        "生物医药ETF",
                        "涨超10%",
                        "涨超3.5%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "新能源主线继续领跑，机构建议布局“跨年行情”",
                "features": {
                    "keywords": [
                        "新能源",
                        "跨年行情"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "新能源"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}